- TAPI and Antheia have formed a strategic partnership to support the commercialisation of biosynthetic key starting materials and active pharmaceutical ingredients.
- The agreement will combine Antheia’s biosynthesis platform with TAPI’s fermentation capabilities and European manufacturing infrastructure.
TAPI has entered a new strategic partnership with Antheia aimed at supporting the commercialisation of Antheia’s biosynthetic key starting materials and active pharmaceutical ingredients. Under the agreement, Antheia will use TAPI’s fermentation capabilities and European manufacturing facilities to scale its pipeline and reduce time to market for future product launches.
The collaboration brings together Antheia’s biosynthesis technology and TAPI’s bioprocessing and manufacturing expertise. According to the press release, TAPI’s existing infrastructure, capacity, and quality management systems align with Antheia’s processes and will support efficient and reliable production at commercial scale. The partnership is intended to benefit multiple products in Antheia’s pipeline and reinforce its long-term commercialisation plans.
With almost a century of API manufacturing experience, TAPI provides the experience and facilities needed to advance Antheia’s supply chain objectives. The partnership also reflects TAPI’s role in combining scientific innovation with manufacturing capability.
The agreement includes a flexible tech-transfer model and a collaborative approach that will support Antheia’s biosynthetic platform. TAPI will contribute fermentation and enzymatic capabilities designed to make complex processes commercially viable.
